Search
Lucinactant
go.drugbank.com/drugs/DB04897ApprovedIt is completely devoid of animal-derived components. FDA approved on March 6, 2012. … More specifically, it mimics the C-terminal amphipathic helical domain of this protein.
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy in August 2023.
Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 2MGSipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data).
Categories: sipuleucel-TSynonyms: Sipuleucel-TRutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalA flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Mixtures: Nutriforte Non-Acidic Vitamin C 1000 mg with BioflavonoidsDigitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p665) … A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting.
Categories: Compounds used in a research, industrial, or household settingProducts: Digimerck 0,07 mg - Tabletten, Digimerck 0,1 mg - TablettenN-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalIt is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated. … N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group.
Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONSynonyms: N-acetyltyrosin, N-acetyltyrosineLevoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationaleffects (Kovoor et al, 2009). … However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideProducts: ELUXAT 84 MG SERT KAPSÜL, CERDELGA® 84 MG CÁPSULA DURAColestipol
go.drugbank.com/drugs/DB00375Approved, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. … [FDA Label, F4555, F4567, L6262] Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism.
Categories: Compounds used in a research, industrial, or household settingLumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.